New 2,4-Diamino-5-(2′,5′-substituted benzyl)pyrimidines as Potential Drugs against Opportunistic Infections of AIDS and Other Immune Disorders. Synthesis and Species-Dependent Antifolate Activity

Journal of Medicinal Chemistry

Volumn 47, Issue 6, 2004, Pages 1475-1486

  Rosowsky, Andre ^a   Forsch, Ronald A ^a   Sibley, Carol Hopkins ^b   Inderlied, Clark B ^c   Queener, Sherry F ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 5 (5' IODO 2' METHOXYBENZYL)PYRIMIDINE; 2,4 DIAMINO [2' METHOXY 5' (3 CARBOXYPHENYL)ETHYNYLBENZYL]PYRIMIDINE; 2,4 DIAMINO [2' METHOXY 5' (4 CARBOXYPHENYL)ETHYNYLBENZYLPYRIMIDINE; ANTINEOPLASTIC AGENT; BENZYL DERIVATIVE; CARBOXYL GROUP; CARBOXYPHENYL DERIVATIVE; DIHYDROFOLATE REDUCTASE INHIBITOR; FUNCTIONAL GROUP; IMMUNOSUPPRESSIVE AGENT; PIRITREXIM; PYRIMIDINE DERIVATIVE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HYDROGENATION; IC 50; IMMUNE DEFICIENCY; IMMUNOPATHOLOGY; MYCOBACTERIUM AVIUM; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS CARINII; SONOGASHIRA REACTION; SPECIES DIFFERENCE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TOXOPLASMA GONDII;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; FOLIC ACID ANTAGONISTS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM; OPPORTUNISTIC INFECTIONS; PNEUMOCYSTIS CARINII; PYRIMIDINES; RATS; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE; TOXOPLASMA;

EID: 1542298076     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030438k     Document Type: Article

References (29)

1. Klepser, M. W.; Klepser, T. B. Drug treatment of HIV-related opportunistic infections. Drugs 1997, 3, 40-73.
2. See ref3 for a selected list of our publications in this area since 1993.
3. Rosowsky, A.; Forsch, R. A.; Queener, S. F. Further studies on 2,4-diamino-5-(2′,5′-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS. J. Med. Chem. 2003, 46, 1726-1736.
4. Rosowsky, A.; Forsch, R. A.; Queener, S. F. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-[2-methoxy-5-(ω-carboxyalkyloxy)benzyl]pyrimidines: Marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim. J. Med. Chem. 2002, 45, 233-241.
5. Kuyper, L. F.; Roth, B.; Baccanari, D. P.; Ferone, R.; Beddell, C. R.; Champness, J. N.; Stammers, D. K.; Dann, J. G.; Norrington, F. E.; Baker, D. J. ; Goodford, P. J. Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues. J. Med. Chem. 1985, 28, 303-311.
6. Calas, M.; Barbieri, A.; Giral, L.; Balmayer, B.; Despaux, E. Synthesis of new trimethoprim analogs. Antibacterial structure-activity relationship. Eur. J. Med. Chem. 1982, 17, 407-504.
7. Havens, S. J.; Hergenrother, P. M. Synthesis of arylacetylenes by the sodium hydride catalyzed cleavage of 4-aryl-2-methyl-3-butyn-2-ols. J. Org. Chem. 1985, 50, 1763-1765.
8. Cody, V.; Rosowsky, A. Crystal structure determination of human DHFR binary complexes with TMP and modeling studies of TMP analogues. Proc. Am. Assoc. Cancer Res. 2002, 43, 1021.
9. Structural studies are planned on the ternary complexes of 15 and 28 with PcDHFR and NADPH in order to determine the 3D orientation of the COOH group in relation to the benzyl moiety (V. Cody, personal communication).
10. Work on the structure of Tg DHFR ternary complexes with several of the compounds in this paper is currently in progress in the laboratory of Dr. Amy Anderson at Dartmouth College and will be reported in due course.
11. Suling, W. J.; Seitz, L. E.; Pathak, V.; Westbrook, L.; Barrow, E. W.; Zywno-van Ginkel, S.; Reynolds, R. C.; Piper, J. R.; Barrow, W. R. Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase. Antimicrob. Agents Chemother. 2000, 44, 2784-2793.
12. Wang, Y.; Bruenn, J. A.; Queener, S. F.; Cody, V. Isolation of rat dihydrofolate reductase gene and characterization of recombinant enzyme. Antimicrob. Agents Chemother. 2001, 45, 2517-2523.
13. Bermudez, L. E.; Inderlied, C. B.; Kolonoski, P.; Petrofsky, M.; Aralar, P.; Wu, M.; Young, L. S. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob. Agents Chemother. 2001, 45, 217-222.
14. We are indebted to Dr. Chris Lambros of the AIDS Opportunistic Infections Program of the NIAID, Bethesda, MD, for kindly arranging to have these assays performed.
15. Raszka, W. V., Jr.; Skillman, L. P.; McEvoy, P. L. In vitro susceptibility of clinical isolates of Mycobacterium avium and M. intracellulare to folate antagonists. Diagn. Microbiol. Infect. Dis. 1994, 18, 201-204.
16. Chang, W. J.; Goetz, M. B. Response to treatment of infection due to Mycobacterium avium complex with trimethoprim-sulfamethoxazole. Clin. Infect. Dis. 1992, 14, 1267-1268.
17. Ji, B.; Lounis, N.; Truffot-Pernot, C.; Grosset, J. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob. Agents Chemother. 1994, 38, 2521-2529.
18. Bermudez, L. L.; Kolonoski, P.; Wu, M.; Aralar, P. A.; Inderlied, C. B.; Young, L. S. Mefloquine is active in vitro and in vivo against Mycobacterium avium complex. Antimicrob. Agents Chemother. 1999, 43, 1870-1874.
19. Bermudez, L. E.; Petrofsky, M.; Kolonoski, P.; Young, L. S. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. Antimicrob. Agents Chemother. 1998, 42, 180-183.
20. Bermudez, L. E.; Inderlied, C. B.; Kolonoski, P.; Petrofsky, M.; Young, L. S. Clarithromycin, dapsone, and a combination of both used to treat of prevent disseminated Mycobacterium avium infection in beige mice. Antimicrob. Agents Chemother. 1994, 38, 2717-2721.
21. Rastogi, N.; Labrousse, V.; Bryskier, A. Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages. Antimicrob. Agents Chemother. 1995, 39, 976-978.
22. Meissner, G.; Anz, W. Sources of Mycobacterium avium complex infection resulting in human diseases. Am. Rev. Respir. Dis. 1977, 116, 1057-1064.
23. Chio, L. C.; Bolyard, L. A.; Nasr, M.; Queener, S. F. Identification of a class of sulfonamides highly active against dihydropteroate synthase from Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium. Antimicrob. Agents Chemother. 1996, 40, 727-733.
24. Brophy, V. H.; Vasquez, J.; Nelson, R. G.; Forney, J. R.; Rosowsky, A.; Sibley, C. H. Identification of Cryptosporidium parvum dihydrofolate reductase inhibitors by complementation in Saccharomyces cerivisiae. Antimicrob. Agents Chemother. 2000, 44, 1019-1028.
25. Lau, H.; Ferlan, J. T.; Brophy, V. H.; Rosowsky, A.; Sibley, C. H. Efficacies of lipophilic inhibitors of dihydrofolate reductase against parasitic protozoa. Antimicrob. Agents Chemother. 2001, 45, 187-195.
26. Hastings, M. D.; Sibley, C. H. Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13137-13141.
27. For a recent critical review of the serious problem of controlling pyrimethamine-resistant malaria in areas of the world where it is endemic, such as sub-Saharan Africa, see the following. Sibley, C. H.; Hyde, J. E.; Sims, P. F. G.; Plowe, C. V.; Kublin, J. G.; Mberu, E. K.; Cowman, A. F.; Winstanley, P. A.; Watkins, W. M.; Nzila, A. M. Trends Parasitol. 2001, 17, 582-588.
28. Motulsky, H. Intuitive Biostatistics; Oxford University Press: New York, 1995; p 286.
29. Gujadhur, R.; Venkataraman, D. Synthesis of diaryl ethers using an easy-to-prepare, air-stable, soluble copper(I) catalyst. Synth. Commun. 2001, 31, 2865-2879.